IMP7068 for Solid Tumors (WEE1 Trial)

Phase 1

Recruiting

Research Sponsored by Impact Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 1 through 30 days after last dose, estimated to be 5 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new drug to see if it is effective and safe in treating advanced solid tumors.

Eligible Conditions

Advanced Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 1 through 30 days after last dose, estimated to be 5 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 1 through 30 days after last dose, estimated to be 5 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 through 30 days after last dose, estimated to be 5 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Part 1 Dose Escalation: Recommended Phase 2 Dose (RP2D) of IMP7068 monotherapy

Part 2 Dose Expansion: Overall Response Rate (ORR)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: IMP7068Experimental Treatment1 Intervention

Part 1: Dose Escalation The study will begin with open-label dose escalation in IMP7068 monotherapy treatment to determine the Maximum tolerated dose (MTD) Part 2: Dose Expansion The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage. A total of 100 patients each with advanced solid tumor who has exhausted available treatment options will be evaluated.

Do I qualify?Apply below to find out